LR

Larry Randall Portfolio

Invests via Alta Partners Management Company LP | Managed by Larry Randall
Invests via Alta Partners Management Company LP
Managed by Larry Randall
Automatically Tracked
Tracking: 0 Updated: Aug 02 at 10:23 AM

Veteran private equity and operations executive focused on middle‑market investments and operational value creation. Larry Randall combines C‑suite operating experience with buyout deal execution, driving margin improvement, carve‑outs and growth strategies across industrial and services sectors. Known for hands‑on portfolio company transformation, capital structuring expertise and board leadership, provides LPs and sponsors strategic sourcing, due diligence and post‑close integration capabilities.

Veteran private equity and operations executive focused on middle‑market investments and operational value creation. Larry Randall combines C‑suite operating experience with buyout deal execution, driving margin improvement, carve‑outs and growth strategies across industrial and services sectors. Known for hands‑on portfolio company transformation, capital structuring expertise and board leadership, provides LPs and sponsors strategic sourcing, due diligence and post‑close integration capabilities.

Investment Philosophy & Strategy

Focuses on middle‑market buyouts and growth carve-outs, blending C‑suite operating discipline with private equity value creation to drive margin expansion and sustainable revenue growth. Prefers control or control-ish investments in industrials and business services where operational redesign, working-capital optimization and capital structure engineering unlock cash flow. Employs hands‑on board leadership and aggressive 100‑day plans, targeting 3–5 year hold periods, risk-adjusted returns through active portfolio management, disciplined underwriting and repeatable exit playbooks.

Focuses on middle‑market buyouts and growth carve-outs, blending C‑suite operating discipline with private equity value creation to drive margin expansion and sustainable revenue growth. Prefers control or control-ish investments in industrials and business services where operational redesign, working-capital optimization and capital structure engineering unlock cash flow. Employs hands‑on board leadership and aggressive 100‑day plans, targeting 3–5 year hold periods, risk-adjusted returns through active portfolio management, disciplined underwriting and repeatable exit playbooks.

Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
-27.08%
Gain +1.01%
Monthly
-9.99%
Yearly
-27.08%
Drawdown
40.17%
$0
Equity
Holdings
$0
Investment
$0
-$17.16M
Profit +$463,517.11
Realized
-$17.16M
Unrealized
$0
Dividends
$0

Goals

Avg. 0% completed goals
Yearly
Gain > 5%
2026
0%
Yearly
Gain < 20%
2026
0%
Today
Compared To Yesterday
Gain
1.01%
Profit
$463,517.11
Win %
33%
This Week
Compared To Last Week
Gain
-7.72%
Profit
-$3.87M
Win %
33%
This Month
Compared to last month
Gain
-15.91%
Profit
-$8.74M
Win %
33%
This Year
Compared to last year
Gain
-27.08%
Profit
-$17.16M
Win %
33%
Allakos Inc. logo
ALLK Allakos Inc.
$0
Tyra Biosciences, Inc. logo
TYRA Tyra Biosciences, Inc.
-$18.77M
Vir Biotechnology Inc. logo
VIR Vir Biotechnology Inc.
-$420,957.2
Loading...

Dividends

Dividend Analysis

Yearly
$
Trades
3
Longs Won
0/3 0%
Profit Factor
-
Profitability
Shorts Won
0/0 0%
Standard Deviation
$10.75M
Average Win
$0
Best Trade
-
Sharpe Ratio
0
Average Loss
-$6.4M
Worst Trade
(Mar 30) -$18.77M
Z-Score
0.35 (27.63%)
Commissions
$0
Avg. Trade Length
2m 4w 1d
Expectancy
-$5.72M
Loss Size 100% 90% 80% 70% 60% 50% 40% 30% 20% 10%
Probability of Loss - - - - - - - - - -
Consecutive Losing Trades
Hover over the desired column for a detailed explanation.

Returns

Overall, Monthly
Symbol Quantity Cost Value Comm. Profit (&#36;) Gain (%) Change
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Tyra Biosciences, Inc - $18.77M and Vir Biotechnology Inc - $420,957.2. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
How stable are Larry Randall's monthly returns?
Larry Randall's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Larry Randall's strategy be considered aggressive or moderate?
It is difficult to clearly classify Larry Randall's strategy as aggressive or moderate based on the available data. A more complete performance and portfolio structure history would be needed to assess the overall risk profile with confidence.
Should beginners follow Larry Randall's strategy?
It is difficult to determine whether Larry Randall's strategy is suitable for beginners based on the available data. A more complete view of performance, risk, and portfolio structure would be needed for a confident assessment.
Account USV